John G Ullman & Associates Inc. Sells 150 Shares of Agilent Technologies, Inc. (NYSE:A)

John G Ullman & Associates Inc. decreased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 0.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,426 shares of the medical research company’s stock after selling 150 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Agilent Technologies were worth $2,736,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its stake in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after acquiring an additional 1,042,926 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Agilent Technologies by 5.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after purchasing an additional 809,149 shares in the last quarter. Marshall Wace LLP lifted its stake in Agilent Technologies by 48.6% during the 2nd quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after acquiring an additional 313,155 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Agilent Technologies by 63.3% in the third quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock valued at $87,075,000 after purchasing an additional 227,431 shares during the last quarter. Finally, Impax Asset Management Group plc lifted its position in shares of Agilent Technologies by 8.2% during the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock worth $396,088,000 after buying an additional 203,234 shares in the last quarter.

Agilent Technologies Price Performance

Shares of NYSE A opened at $128.57 on Thursday. The company has a 50 day simple moving average of $138.06 and a two-hundred day simple moving average of $137.76. The company has a market capitalization of $36.94 billion, a price-to-earnings ratio of 26.67, a P/E/G ratio of 5.59 and a beta of 1.07. Agilent Technologies, Inc. has a fifty-two week low of $121.23 and a fifty-two week high of $155.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the firm posted $1.43 earnings per share. The business’s revenue was down 5.6% on a year-over-year basis. Analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were given a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 annualized dividend and a dividend yield of 0.73%. Agilent Technologies’s dividend payout ratio (DPR) is presently 19.50%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on A shares. Evercore ISI increased their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Stifel Nicolaus reissued a “buy” rating and set a $151.00 price objective on shares of Agilent Technologies in a report on Monday, August 26th. TD Cowen lifted their price objective on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Wells Fargo & Company initiated coverage on Agilent Technologies in a research note on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price target for the company. Finally, UBS Group upped their price objective on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $144.36.

Insider Activity

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.